|
1
|
Friedman HS, McLendon RE, Kerby T, Dugan
M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K,
et al: DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase
analysis and response to Temodal in newly diagnosed malignant
glioma. J Clin Oncol. 16:3851–3857. 1998.PubMed/NCBI
|
|
2
|
Esteller M, Garcia-Foncillas J, Andion E,
Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB and Herman JG:
Inactivation of the DNA-repair gene MGMT and the clinical response
of gliomas to alkylating agents. N Engl J Med. 343:1350–1354. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stupp R, Hegi ME, Mason WP, van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al: European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups; National
Cancer Institute of Canada Clinical Trials Group: Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Weiler M, Hartmann C, Wiewrodt D,
Herrlinger U, Gorlia T, Bähr O, Meyermann R, Bamberg M, Tatagiba M,
von Deimling A, et al: Chemoradiotherapy of newly diagnosed
glioblastoma with intensified temozolomide. Int J Radiat Oncol Biol
Phys. 77:670–676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reifenberger G, Hentschel B, Felsberg J,
Schackert G, Simon M, Schnell O, Westphal M, Wick W, Pietsch T,
Loeffler M, et al: German Glioma Network: Predictive impact of MGMT
promoter methylation in glioblastoma of the elderly. Int J Cancer.
131:1342–1350. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gállego Pérez-Larraya J, Ducray F, Chinot
O, Catry-Thomas I, Taillandier L, Guillamo JS, Campello C, Monjour
A, Cartalat-Carel S, Barrie M, et al: Temozolomide in elderly
patients with newly diagnosed glioblastoma and poor performance
status: An ANOCEF phase II trial. J Clin Oncol. 29:3050–3055. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wick W, Platten M, Meisner C, Felsberg J,
Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M,
et al: NOA-08 Study Group of Neuro-oncology Working Group (NOA) of
German Cancer Society: Temozolomide chemotherapy alone versus
radiotherapy alone for malignant astrocytoma in the elderly: The
NOA-08 randomised, phase 3 trial. Lancet Oncol. 13:707–715. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malmström A, Grønberg BH, Marosi C, Stupp
R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi
ME, et al: Nordic Clinical Brain Tumour Study Group (NCBTSG):
Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with
glioblastoma: The Nordic randomised, phase 3 trial. Lancet Oncol.
13:916–926. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schwarzenbach H, Hoon DS and Pantel K:
Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev
Cancer. 11:426–437. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lavon I, Refael M, Zelikovitch B, Shalom E
and Siegal T: Serum DNA can define tumor-specific genetic and
epigenetic markers in gliomas of various grades. Neuro Oncol.
12:173–180. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Esteller M, Hamilton SR, Burger PC, Baylin
SB and Herman JG: Inactivation of the DNA repair gene
O6-methylguanine-DNA methyltransferase by promoter hypermethylation
is a common event in primary human neoplasia. Cancer Res.
59:793–797. 1999.PubMed/NCBI
|
|
13
|
Diehl F, Schmidt K, Choti MA, Romans K,
Goodman S, Li M, Thornton K, Agrawal N, Sokoll L, Szabo SA, et al:
Circulating mutant DNA to assess tumor dynamics. Nat Med.
14:985–990. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoon KA, Park S, Lee SH, Kim JH and Lee
JS: Comparison of circulating plasma DNA levels between lung cancer
patients and healthy controls. J Mol Diagn. 11:182–185. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chan KC and Lo YM: Circulating
tumour-derived nucleic acids in cancer patients: Potential
applications as tumour markers. Br J Cancer. 96:681–685. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chan KC, Lai PB, Mok TS, Chan HL, Ding C,
Yeung SW and Lo YM: Quantitative analysis of circulating methylated
DNA as a biomarker for hepatocellular carcinoma. Clin Chem.
54:1528–1536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Usadel H, Brabender J, Danenberg KD,
Jerónimo C, Harden S, Engles J, Danenberg PV, Yang S and Sidransky
D: Quantitative adenomatous polyposis coli promoter methylation
analysis in tumor tissue, serum, and plasma DNA of patients with
lung cancer. Cancer Res. 62:371–375. 2002.PubMed/NCBI
|
|
18
|
Umetani N, Giuliano AE, Hiramatsu SH,
Amersi F, Nakagawa T, Martino S and Hoon DS: Prediction of breast
tumor progression by integrity of free circulating DNA in serum. J
Clin Oncol. 24:4270–4276. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sunami E, Shinozaki M, Higano CS, Wollman
R, Dorff TB, Tucker SJ, Martinez SR, Mizuno R, Singer FR and Hoon
DS: Multimarker circulating DNA assay for assessing blood of
prostate cancer patients. Clin Chem. 55:559–567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hisazumi J, Kobayashi N, Nishikawa M and
Takakura Y: Significant role of liver sinusoidal endothelial cells
in hepatic uptake and degradation of naked plasmid DNA after
intravenous injection. Pharm Res. 21:1223–1228. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tsang JC and Lo YM: Circulating nucleic
acids in plasma/serum. Pathology. 39:197–207. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hoque MO, Topaloglu O, Begum S, Henrique
R, Rosenbaum E, Van Criekinge W, Westra WH and Sidransky D:
Quantitative methylation-specific polymerase chain reaction gene
patterns in urine sediment distinguish prostate cancer patients
from control subjects. J Clin Oncol. 23:6569–6575. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fackler MJ, Malone K, Zhang Z, Schilling
E, Garrett-Mayer E, Swift-Scanlan T, Lange J, Nayar R, Davidson NE,
Khan SA, et al: Quantitative multiplex methylation-specific PCR
analysis doubles detection of tumor cells in breast ductal fluid.
Clin Cancer Res. 12:3306–3310. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weber M, Davies JJ, Wittig D, Oakeley EJ,
Haase M, Lam WL and Schübeler D: Chromosome-wide and
promoter-specific analyses identify sites of differential DNA
methylation in normal and transformed human cells. Nat Genet.
37:853–862. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kagan J, Srivastava S, Barker PE, Belinsky
SA and Cairns P: Towards Clinical Application of Methylated DNA
Sequences as Cancer Biomarkers: A Joint NCI's EDRN and NIST
Workshop on Standards, Methods, Assays, Reagents and Tools. Cancer
Res. 67:4545–4549. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Paci M, Maramotti S, Bellesia E, Formisano
D, Albertazzi L, Ricchetti T, Ferrari G, Annessi V, Lasagni D,
Carbonelli C, et al: Circulating plasma DNA as diagnostic biomarker
in non-small cell lung cancer. Lung Cancer. 64:92–97. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vlassenbroeck I, Califice S, Diserens AC,
Migliavacca E, Straub J, Di Stefano I, Moreau F, Hamou MF, Renard
I, Delorenzi M, et al: Validation of real-time methylation-specific
PCR to determine O6-methylguanine-DNA methyltransferase gene
promoter methylation in glioma. J Mol Diagn. 10:332–337. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu BL, Cheng JX, Zhang W, Zhang X, Wang
R, Lin H, Huo JL and Cheng H: Quantitative detection of multiple
gene promoter hypermethylation in tumor tissue, serum, and
cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro
Oncol. 12:540–548. 2010. View Article : Google Scholar : PubMed/NCBI
|
